This inquiry initially showed up on Quora. Answer by Alex K. Chen.
Short rundown: Adderall/Dexedrine can be neurotoxic over the long haul (by harming dopamine neurons) while Ritalin doesn’t have as much neurotoxicity potential. Shockingly, when Ritalin and Adderall are combined as one, Ritalin can really assist with checking Adderall’s neurotoxicity potential.
Regardless of whether Adderall’s neurotoxicity applies to the individuals who take dosages pertinent to ADD is indistinct. The majority of the examinations use amphetamine does higher than those utilized for treating ADHD, yet Amphetamine Treatment Similar to That Used in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder Damages Dopaminergic Nerve Endings in the Striatum of Adult Nonhuman Primates utilizes portions like those utilized for treating ADHD (however I don’t know whether this paper shows neurotoxicity instead of simple downregulation).
Resilience can occur with either, yet resistance isn’t neurotoxicity as it tends to be turned around by enjoying reprieves.
At the point when one takes both of these medications when youthful, there can be unobtrusive formative impacts as well. They could prompt neurons “accepting” that there is more dopamine than there really is, which could prompt develop circuits with decreased dopamine flagging once they completely develop (see Performance improvement at the expense of potential cerebrum versatility: neural consequences of nootro… for additional subtleties).
So in short – there are three impacts: resilience, neurotoxicity, and formative. Resilience is reversible, while neurotoxicity isn’t. Formative impacts are the most convoluted, and still hard to enough sum up.
It relies upon many elements
(I will utilize the word dexedrine reciprocally with Adderall, since they’re for the most part comparative – Adderall is 75% d-amphetamine and 25% l-amphetamine, and Dexedrine is 100% d-amphetamine)
As somebody with ADD who has been worried about their drawn out impacts, I have done a tremendous measure of examination into this.
Above all else, in regards to the cardiovascular dangers: http://www.sciencedaily.com/rele… shows that there is no expansion in serious cardiovascular occasions for youngsters with no prior heart irregularities. This could be diverse for more seasoned grown-ups who might be more defenseless against getting respiratory failures, be that as it may. Most youngsters shouldn’t stress over the cardiovascular impacts.
Taking both of them could bring about resilience (seehttp://dx.doi.org/10.1016/S0006-… – talked about in , and Long-Term Stimulant Treatment Affects Brain Dopamine Transporter Level in Patients with Attention Deficit Hyperactive Disorder ). This implies that you might have to get higher dosages over the long run to accomplish a similar impact. Nonetheless, various individuals with ADD can accomplish a steady portion of one or the other medication after some time. Regardless, resilience is reversible, and you can forestall it by enjoying reprieves every so often.
 Link shows that both amphetamine and methylphenidate produce deficiencies in striatal dopamine markers after treatment, yet that the markers recuperated in methylphenidate-treated mice yet not amphetamine-treated ones (demonstrating something reversible in methylphenidate yet potentially not amphetamine). Despite the fact that it didn’t distinguish the component and a 2-week holding up period may not be sufficient to extrapolate extremely durable impacts
http://neurosciencenews.com/adhd… is a potential instrument of resilience (obviously, the cerebrum repays by expanding the quantity of DAT carriers). Likewise see Long-Term Stimulant Treatment Affects Brain Dopamine Transporter Level in Patients with Attention Deficit Hyperactive Disorder
Presently to examine the potential impacts past resilience:
There is a genuine distinction between the two, notwithstanding. Adderall is a dopamine discharge specialist, while Ritalin is a dopamine reuptake inhibitor. The two of them increment dopamine motioning by expanding the measure of dopamine in the neurotransmitter (so more dopamine winds up restricting to the dopamine receptors in the postsynaptic neuron). The key distinction is their activity on the dopamine carrier, which by and large moves a great deal of the dopamine in the neurotransmitter back into the presynaptic neuron – which decreases the measure of dopamine in the neural connection, and dopamine flagging. Ritalin expands dopamine motioning by adequately obstructing the dopamine carrier. In the interim, Adderall does it by switching the activity of the dopamine carrier, which successfully powers considerably more dopamine into the neurotransmitter (where it can expand dopamine flagging significantly further).
There is another contrast between the two: and that distinction is identified with the action of the VMAT-2 carrier. This carrier adequately ships dopamine from the cell cytosol into synaptic vesicles (presented underneath), which viably sequesters up the dopamine and keeps it from corruption by MAO compounds + auto-oxidation. The thing that matters is this: Amphetamine successfully represses the movement of the VMAT-2 carrier, so it bundles up less dopamine. Methylphenidate (the compound name for Ritalin), then again, upgrades the movement of the carrier. What’s more, this distinction is really what makes amphetamine neurotoxic and methylphenidate similarly harmless. The thing is, dopamine is an exceptionally receptive particle when it isn’t bundled by VMAT-2, and when it autooxidizes in the presynaptic cytosol, it can really harm the presynaptic terminal. Amphetamine speeds up this, and causes presynaptic terminal harm. In the interim, methylphenidate keeps it from occurring.
Shockingly enough, this produces intriguing outcomes, which prompted this paper: http://jpet.aspetjournals.org/co…. Fundamentally, that paper shows that methylphenidate really constricted the deficiencies related with harm incited by (methamphetamine does all the harm of amphetamine , yet adds A LOT to that harm). So shockingly enough, methylphenidate really can lessen the neurotoxicity related with amphetamine, whenever brought with it. Remember, however, that methylphenidate has a more limited half-life than amphetamine.
A portion of dopamine’s neurotoxicity is brought about by monoamine oxidase A (MAO) in the presynaptic terminal. At the point when MAO catalyzes the debasement of dopamine, hydrogen peroxide (H2O2) is delivered thus, and this H2O2 can proceed to harm the presynaptic terminal. Methylphenidate viably decreases the measure of MAO debasement of dopamine in the presynaptic terminal by impeding dopamine reuptake – this lessens the measure of H2O2 delivered (yet dopamine can in any case be corrupted in the extracellular neurotransmitter and it’s muddled if this likewise harms).
Has amphetamine’s neurotoxicity (comparative with methylphenidate) been tentatively illustrated?
Here’s one of the papers (http://jpet.aspetjournals.org/co…
As the utilization of amphetamine in the treatment of ADHD has expanded, an enormous assortment of preclinical information has accumulated demonstrating that amphetamine can possibly harm cerebrum dopamine-containing neurons in trial creatures. Specifically, creatures treated with amphetamine foster enduring decreases in striatal dopamine, its significant metabolite dihydroxyphenylacetic corrosive (DOPAC), its rate-restricting compound tyrosine hydroxylase, its film carrier (DAT), and its vesicular carrier (VMAT2) (Gibb et al., 1994; McCann and Ricaurte, 2004). Anatomic examinations show that enduring dopaminergic shortages after amphetamine are because of harm of dopaminergic sensitive spots in the striatum, with saving of dopaminergic nerve cell bodies in the substantia nigra.
Specifically, the aftereffects of the current investigation show that an oral routine of amphetamine, displayed in the wake of dosing regimens utilized in patients with ADHD, incites plasma amphetamine fixations that outcome in harmfulness to cerebrum dopaminergic axon terminals in mandrills and squirrel monkeys. These outcomes might have suggestions for the pathophysiology and therapy of ADHD and bring up the issue of whether plasma observing may be demonstrated in ADHD patients getting higher, persistent portions of amphetamine.
At any rate, here’s another generally excellent string examining this topic: http://www.longecity.org/gathering/t…
Also, an exceptionally far reaching lit audit article (examines what I said here + more): http://www.ncbi.nlm.nih.gov/pmc/…
That all being said, amphetamine’s belongings are not all around terrible. It can build neurogenesis, maybe on the grounds that numerous people with ADD are diverted to such an extent that their interruption viably represses neural pathways from shaping. Amphetamine/methylphenidate can assist with advancing the development of these neural pathways by lessening this clamor. See beneath:
In early examinations, high portions of amphetamine, tantamount to sums utilized by addicts, were displayed to harm dopaminergic pathways. Later examinations, utilizing helpful regimens, seem opposing. One worldview shows critical reductions in striatal dopamine and carrier thickness after oral organization of “remedial” dosages in primates. Another shows morphological proof of “trophic” dendritic development in the cerebrums of grown-up and adolescent rodents given foundational infusions emulating “remedial” treatment. Imaging investigations of ADHD-analyzed people show an increment in striatal dopamine carrier accessibility that might be diminished by methylphenidate treatment.
What’s more, from the referenced lit survey (http://www.ncbi.nlm.nih.gov/pmc/…
As opposed to worries about possible unfavorable impacts of amphetamine on the cerebrum during maturing, it is amazing that the decrease of the increased danger for substance misuse that is generally connected with ADHD by the commencement of energizer treatment during youth gives off an impression of being joined by a harmonious decrease in primary mind pathology.